sector medic suppli devic
messag revenu yoy came
street upsid ou omnipod busi off-set
slight miss drug deliveri segment elsewher updat coverag
european transit dash horizon program gener posit set
steadi cadenc new growth driver next month
guidanc came consensu see revenu growth midpoint
good enough given investor concern outlook come call
guidanc come consensu anoth year solid growth still tap
conjunct call manag issu revenu guidanc
compar current consensu omnipod sale
expect come intern revenu forecast
final drug deliveri sale project
begin feel impact gener competit neulasta three
compon believ drug deliveri piec repres biggest shortfal rel
consensu omnipod outlook also modestli wors
street model sens come week stock alreadi reflect investor
worri potenti lower guid concern share especi
given larg number move piec involv busi plan one item
believ could still lead volatil number move year
transit dash mobil platform manag describ full year
impact revenu neutral assum higher pod price abl off-set lost
sale balanc act suspect could thrown depend pace adopt
regardless continu view dash major leap forward omnipod patient
experi import facilit move pharmaci
enabl greater patient access volum futur
turn back quarter better-than-expect omnipod sale made
shortfal drug deliveri omnipod revenu rose beat
consensu new patient start remain strong come record level
third straight quarter meanwhil intern omnipod sale ahead
street cc final drug deliveri sale fell came
street expect remain cautiou segment given challeng
long-term trajectori neulasta face gener competit concern reflect
manag guidanc piec busi
momentum core omnipod busi remain strong estim
world-wide custom base grew patient growth domest
increas ou broader payer coverag increas access pharmaci
channel drive adopt pharmaci sale account omnipod
revenu transit direct sale forc intern pay dividend
go forward look ahead benefit recent progress
made payer expect full roll-out dash mobil platform
gener signific buzz among patient note howev dash launch
also add increment layer complex outlook lower up-front
revenu new patient start made time higher pod
impact smooth move year
meanwhil regulatori timelin horizon ap program unchang
manag still target fda approv somewhat late
game first close loop offer think horizon potenti win
patient given simplic patch pump form factor novel featur like
direct smartphon control meanwhil expect receiv fda approv use
omnipod concentr insulin yearend increas
compani appeal type patient compat formul expect
seen bigger opportun
page analyst certif import disclosur
incom statement reduc opex allow top line beat flow
earn report gross margin yoy
consensu driven benefit eu sale forc transit
on-going productivity/cost improv compani continu make progress drive
manufactur effici gross margin expand overal
progress front expect limit new manufactur
facil ramp product longer-tern howev manag remain confid
goal hit gm elsewher sg expens rose yoy
sale street estim leverag partial off-set
 spend rose yoy revenu consensu
combin drove ep vs street forecast power
full year profit oper net basi first time
anoth year solid growth tap reiter buy model call
post ep total revenu compar
prior forecast respect long-term confid
insulet abil sustain top line growth trajectori unchang
maintain price target base multipl
forward ntm revenu estim signific upsid potenti target current
level reiter buy rate share
page analyst certif import disclosur
develop insulin infus system peopl insulin-depend diabet
compani omnipod system novel dispos patch pump believ offer
varieti advantag tradit durabl insulin pump includ elimin
tube connect pump patient improv comfort increas conveni
attribut allow carv meaning posit insulin pump
market estim top world-wide revenu last year
believ compani continu take share go forward driven recent
competitor exit market launch new dash mobil platform shift
direct sale europ label expans includ concentr insulin formul
estim could effect doubl omnipod address market open
type opportun take factor account see
posit sustain top line growth next year view
growth outlook least partial reflect stock current level believ
continu execut steadi cadenc pipelin oper catalyst next
month scarciti compar growth stori across small-cap
med-tech univers drive continu out-performance
valu primarili ev/sal basi use repres group small-to-
mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade
ntm sale premium multipl maintain
price target base previous multipl forward ntm
sale estim signific upsid potenti target current level assign
downsid risk rate price target includ failur keep pace
innov competitor caus omnipod adopt fall short street
expect disrupt compani product suppli chain faster
anticip penetr neulasta biosimilar could neg impact
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
revenu geographi
compani report guggenheim secur llc estim
page analyst certif import disclosur
